Volume : 12, Issue : 06, June – 2025
Title:
FORMULATION AND EVALUATION OF LOVASTATIN TRANSDERMAL PATCHES
Authors :
Dr.T.Mangilal*, Mrs.T.Sowmya, Lokam Neeraja, Suppa Anusha, Mohd. Mudassir,T. Ruthika Goud, M. swetha
Abstract :
Abstract:
The skin can be used as the site for drug administration for continuous transdermal drug infusion into the systemic circulation. For the continuous diffusion/penetration of the drugs through the intact skin surface membrane-moderated systems, matrix dispersion type systems, adhesive diffusion-controlled systems and micro reservoir systems have been developed.
In the present work, an attempt has been made to develop a matrix-type transdermal therapeutic system comprising of Lovastatin with different ratios of polymers Eudragit L100 and Ethyl Cellulose using solvent evaporation techniques. The physicochemical compatibility of the drug and the polymers was studied by FTIR. The results obtained showed no physical-chemical incompatibility between the drug and the polymers. F8 formulation has been selected as the optimized formulation among all the other formulations because of the highest concentration of penetrating enhancer with the highest concentration of ethyl cellulose. The in vitro drug diffusion studies from the formulation were found to be released (99.36 ± 2.04 %) up to 12 hours. All the evaluation parameters obtained from the best formulation were found to be satisfactory.
Keywords: Lovastatin, Permeation Enhancer, and Transdermal drug delivery.
Cite This Article:
Please cite this article in press T.Mangilal et al, Formulation And Evaluation Of Lovastatin Transdermal Patches.., Indo Am. J. P. Sci, 2025; 12(07).
Number of Downloads : 10
References:
1.Chien Y.W. “Novel Drug Delivery Systems”, (2nd Ed), Drugs and Pharmaceutical Sciences, Volume-50, Marcel Dekker, Inc.
2.Finnin B C, Morgan T M, Transdermal penetration. J Pharm Sci. Oct 1999; 88 (10): 955-958.
3.Allen LV, Popovich NG, Ansel HC, Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems, (8th Ed), Lippincott Williams &Wilkins, 2005: 298- 315.
4.Barry B. Transdermal Drug Delivery. In Ed: Aulton ME, Pharmaceutics: The Science of Dosage Form Design, Churchill Livingston. 2002:4 99-533.
5.Cleary GW, Transdermal controlled release systems. Medical Applications of Controlled Release. 1: 203-251.
6.Vyas SP, Khar RK, Controlled Drug Delivery: Concepts and Advances, Vallabh Prakashan, (1st Ed). 2002: 411-447.
7.Tortora G, Grabowski S. The Integumentary system. In: Principles of Anatomy and Physiology. (9th ed). John Wiley and Sons Inc. 150-151.
8.Wilson K J W, Waugh A. Eds, “Ross and Wilson: Anatomy and Physiology In Health And Illness”, (8th Ed), Churchill Livingstone. 1996: 360-366.
9.Gupta JRD, Irchiayya R, Garud N. “Formulation and evaluation of matrix type transdermal patches of Glibenclamide”, International Journal of Pharmaceutical Sciences Development and Research, 2009; 1(1): 46-50.
10.Kenneth A. Walters, Michael s. Roberts; Dermatological and Transdermal Formulations; 204-241.
11.Oh SY, Jeong SY, Park TG, Lee JH. Enhanced transdermal delivery of AZT (Zidovudine) using iontophoresis and penetration enhancer. Journal of Control Release.1998 Feb 12; 51(2-3):161-8.
12.Inayat Bashir Pathan, C Mallikarjuna Setty; Chemical Penetration Enhancers for Transdermal Drug Delivery Systems; Tropical Journal of Pharmaceutical Research, April 2009; 8 (2): 173-179.
13.Ashok K. Tiwari, Bharti Sapra and Subheet Jain, Innovations in Transdermal Drug Delivery: Formulations and Techniques, Recent Patents on Drug Delivery & Formulation 2007; 1: 23-36.